OliX Pharmaceuticals, Inc.
KOSDAQ-listed RNAi biotech developing and out-licensing therapeutics based on its proprietary self-delivering asymmetric siRNA (cp-asiRNA) platform.
As of 2026-10-11, OliX Pharmaceuticals, Inc. has 15 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2010 and listed on KOSDAQ in 2018, OliX Pharmaceuticals is a drug developer specializing in RNA interference (RNAi) platform technology. It has secured proprietary self-delivering asymmetric siRNA (cp-asiRNA) technology to develop therapeutics for intractable diseases, improving intracellular delivery efficiency by conjugating hydrophobic moieties for extrahepatic delivery and using GalNAc with its own proprietary linker for liver delivery, and is also developing the next-generation GalNAc-bi-asiRNA platform capable of targeting two genes simultaneously. Its technology can target any gene through sequence changes alone and shortens candidate selection to under one year, and the company monetizes its RNAi platform and pipeline-related technologies by licensing them to domestic and international pharmaceutical companies.
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1/2 · Recruiting · 2025-12 · NCT07327359
Phase 1 · Completed · 2023-01 · NCT05643118
Phase 2 · Completed · 2021-08 · NCT04877756
Phase 1 · Completed · 2018-05 · NCT03569267
R&D and key agreements
Source: DART corporate disclosurecp-asiRNA(자가전달 비대칭 siRNA) · 플랫폼 기술 · Proprietary self-delivering asymmetric siRNA platform; candidate selection shortened to under one year
GalNAc-bi-asiRNA · 연구개발중 · Next-generation platform capable of targeting two genes simultaneously
Key disclosures
KRX KIND via OpenDARTShow 7 more events
Publications
PubMed · affiliation-matched- Cell-penetrating asymmetric siRNA targeting MyD88 suppresses inflammasome-driven ocular degeneration and angiogenesis.
Molecular therapy : the journal of the American Society of Gene Therapy · 2026-09 · Kim J, Min S, Yum M 외 8
- Transient Knockdown of RORB with Cell-Penetrating siRNA Improves Visual Function in a Proteotoxic Mouse Model of Retinitis Pigmentosa.
Biomedicines · 2025-09 · Son C, Lee HK, Jang H 외 6
- In vivo efficacy of NRL knockdown with cell-penetrating siRNA in retinal degeneration.
Scientific reports · 2025-07 · Lee H, Jang H, Chae JB 외 12
- Nonclinical Pharmacokinetics Study of OLX702A-075-16, N-Acetylgalactosamine Conjugated Asymmetric Small Interfering RNA (GalNAc-asiRNA).
Drug metabolism and disposition: the biological fate of chemicals · 2024-10 · Ban J, Seo BK, Yu Y 외 6
- Development of Long Asymmetric siRNA Structure for Target Gene Silencing and Immune Stimulation in Mammalian Cells.
Nucleic acid therapeutics · 2023-10 · Kim S, Kang YG, Kim J 외 2
- Efficacy of Asymmetric siRNA Targeting Androgen Receptors for the Treatment of Androgenetic Alopecia.
Molecular pharmaceutics · 2023-01 · Moon IJ, Yoon HK, Kim D 외 7
- RIG-I-Mediated Innate Immune Stimulation by Chemically Synthesized Long Double-Stranded RNAs Is Structure and Sequence Dependent.
Nucleic acid therapeutics · 2022-08 · Kang YG, Kim J, Lee K 외 3
- Prenatal developmental toxicity study of 2,4-dichlorobenzyl alcohol in rats.
Regulatory toxicology and pharmacology : RTP · 2022-07 · Moon KN, Baek SK, Kim W 외 8
- Endothelial Unc5B controls blood-brain barrier integrity.
Nature communications · 2022-03 · Boyé K, Geraldo LH, Furtado J 외 11
- L-Type Calcium Channel Blocker Enhances Cellular Delivery and Gene Silencing Potency of Cell-Penetrating Asymmetric siRNAs.
Molecular pharmaceutics · 2020-03 · Choe JY, Son DS, Kim Y 외 8
Show 5 more publications
- ALPPL2 Is a Potential Diagnostic Biomarker for Pancreatic Cancer-Derived Extracellular Vesicles.
Molecular therapy. Methods & clinical development · 2019-12 · Shin HS, Jung SB, Park S 외 2
- Tripodal RNA with 3' Overhangs Prevents RIG-I-Mediated Innate Immune Response.
Nucleic acid therapeutics · 2019-10 · Kang YG, Choe JY, Lee S 외 4
- Cell-SELEX-Based Identification of a Human and Mouse Cross-Reactive Endothelial Cell-Internalizing Aptamer.
Nucleic acid therapeutics · 2018-08 · Dua P, Kang S, Shin HS 외 2
- RNA Interference-Mediated Gene Silencing by Branched Tripodal RNAs Does Not Require Dicer Processing.
Nucleic acid therapeutics · 2018-02 · Kim Y, Kang YG, Choe JY 외 4
- Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor.
The Journal of investigative dermatology · 2016-11 · Hwang J, Chang C, Kim JH 외 8
Patents
KIPRIS · applicant-matchedPCT · Published · 2025-09 · Application PCT/KR2025/013714
Published · 2025-08 · Application 1020250121488
PCT · Published · 2025-08 · Application PCT/KR2025/013220
Published · 2024-12 · Application 1020240180823
Published · 2024-12 · Application 1020240180822
Published · 2024-12 · Application 1020240180824
Published · 2024-09 · Application 1020240121802
PCT · Published · 2024-04 · Application PCT/KR2024/004361
CN · Published · 2024-03 · Application 202480017344.5
Published · 2024-03 · Application 1020257028859
Show 141 more patents
EP · Published · 2024-03 · Application 24767458.3
PCT · Published · 2024-03 · Application PCT/KR2024/003039
PCT · Published · 2024-03 · Application PCT/KR2024/003026
Rejected · 2023-12 · Application 1020230181707
Registered · 2023-09 · Application 1020230126519
Registered · 2023-06 · Application 1020230076946
Registered · 2023-04 · Application 1020230046567
Registered · 2022-12 · Application 1020220185677
Registered · 2022-12 · Application 1020220185678
Rejected · 2022-12 · Application 1020220170932
Withdrawn · 2022-10 · Application 1020220142893
Registered · 2022-10 · Application 1020220139030
PCT · Published · 2022-09 · Application PCT/KR2022/013822
Registered · 2022-07 · Application 1020220085888
CN · Published · 2022-07 · Application 202280048413.X
US · Published · 2022-07 · Application 18577278
Published · 2022-07 · Application 1020220084498
EP · Published · 2022-07 · Application 22838056.4
PCT · Published · 2022-07 · Application PCT/KR2022/009984
Published · 2022-01 · Application 1020220006534
Published · 2022-01 · Application 1020220006304
Published · 2022-01 · Application 1020220006533
CN · Published · 2021-12 · Application 202180082383.X
US · Published · 2021-12 · Application 18267885
Registered · 2021-12 · Application 1020210183087
EP · Published · 2021-12 · Application 21907187.5
PCT · Published · 2021-12 · Application PCT/KR2021/019408
PCT · Published · 2021-12 · Application PCT/KR2021/018460
CN · Published · 2021-12 · Application 202180081765.0
US · Published · 2021-12 · Application 18265603
Registered · 2021-12 · Application 1020210173271
EP · Published · 2021-12 · Application 21903785.0
PCT · Published · 2021-12 · Application PCT/KR2021/018386
Abandoned · 2021-09 · Application 1020210129740
Registered · 2021-02 · Application 1020210026083
Registered · 2020-12 · Application 1020200177534
Rejected · 2020-12 · Application 1020200169854
US · Published · 2020-12 · Application 17110640
Rejected · 2020-11 · Application 1020200162171
Rejected · 2020-11 · Application 1020200162173
Rejected · 2020-11 · Application 1020200162170
Rejected · 2020-11 · Application 1020200162172
Registered · 2020-09 · Application 1020200117845
CN · Published · 2020-08 · Application 202080101422.1
US · Registered · 2020-08 · Application 17927427
Registered · 2020-08 · Application 1020200102064
Registered · 2020-08 · Application 1020200102065
EP · Published · 2020-08 · Application 20937285.3
PCT · Published · 2020-08 · Application PCT/KR2020/010787
PCT · Published · 2020-08 · Application PCT/KR2020/010781
US · Published · 2020-05 · Application 17612845
Registered · 2020-05 · Application 1020200060495
EP · Published · 2020-05 · Application 20809923.4
PCT · Published · 2020-05 · Application PCT/KR2020/006610
Registered · 2020-01 · Application 1020200006755
PCT · Published · 2020-01 · Application PCT/KR2020/000870
Registered · 2020-01 · Application 1020217023892
PCT · Published · 2020-01 · Application PCT/IB2020/050097
PCT · Published · 2019-12 · Application PCT/KR2019/017332
Registered · 2019-11 · Application 1020190140951
US · Published · 2019-10 · Application 16667398
US · Registered · 2019-07 · Application 16514569
US · Registered · 2019-04 · Application 16380638
US · Registered · 2018-12 · Application 16220030
Rejected · 2018-12 · Application 1020180158149
US · Published · 2018-10 · Application 16151867
Rejected · 2018-09 · Application 1020180115669
PCT · Published · 2018-09 · Application PCT/KR2018/011482
US · Registered · 2018-09 · Application 16135766
Withdrawn · 2018-08 · Application 1020180101485
Withdrawn · 2018-08 · Application 1020180101482
Withdrawn · 2018-08 · Application 1020180101483
Withdrawn · 2018-08 · Application 1020180101484
US · Registered · 2018-08 · Application 16102155
US · Registered · 2018-07 · Application 16042833
CN · Published · 2018-02 · Application 201880026212.3
US · Registered · 2018-02 · Application 16486833
EP · Registered · 2018-02 · Application 18758086.5
PCT · Published · 2018-02 · Application PCT/KR2018/002103
JP · Registered · 2018-02 · Application 31566555
US · Registered · 2018-02 · Application 16484643
Rejected · 2018-02 · Application 1020197025890
Withdrawn · 2017-12 · Application 1020170184723
Withdrawn · 2017-12 · Application 1020170184722
Withdrawn · 2017-08 · Application 1020170111003
US · Registered · 2017-06 · Application 16313754
EP · Registered · 2017-06 · Application 17820560.5
Registered · 2017-06 · Application 1020170081063
CN · Published · 2017-04 · Application 201780022913.5
US · Registered · 2017-04 · Application 15483305
Registered · 2017-04 · Application 1020187029205
EP · Published · 2017-04 · Application 17781996.8
PCT · Published · 2017-04 · Application PCT/IB2017/000470
Withdrawn · 2017-03 · Application 1020170029678
Withdrawn · 2017-03 · Application 1020170029677
Registered · 2017-02 · Application 1020170022909
CN · Published · 2017-02 · Application 201780015900.5
CN · Published · 2017-02 · Application 201780015898.1
US · Registered · 2017-02 · Application 15422186
US · Registered · 2017-02 · Application 15422122
Registered · 2017-02 · Application 1020187024039
Registered · 2017-02 · Application 1020187024040
EP · Registered · 2017-02 · Application 17747070.5
EP · Published · 2017-02 · Application 17747071.3
PCT · Published · 2017-02 · Application PCT/IB2017/000167
PCT · Published · 2017-02 · Application PCT/IB2017/000166
JP · Registered · 2016-12 · Application 28250474
Withdrawn · 2016-12 · Application 1020160170603
Abandoned · 2016-11 · Application 1020160153358
CN · Published · 2016-11 · Application 201680078793.6
US · Registered · 2016-11 · Application 15352322
Registered · 2016-11 · Application 1020187015145
EP · Published · 2016-11 · Application 24195470.0
EP · Published · 2016-11 · Application 16865834.2
PCT · Published · 2016-11 · Application PCT/IB2016/001745
Registered · 2016-11 · Application 1020160147969
US · Registered · 2016-07 · Application 15220767
CN · Published · 2016-07 · Application 201680055214.6
Registered · 2016-07 · Application 1020187004802
PCT · Published · 2016-07 · Application PCT/IB2016/001169
Withdrawn · 2016-03 · Application 1020160038833
Withdrawn · 2016-03 · Application 1020160038834
Rejected · 2015-12 · Application 1020150175541
Rejected · 2015-12 · Application 1020150175585
Registered · 2015-09 · Application 1020150136206
Withdrawn · 2015-08 · Application 1020150122491
Registered · 2014-04 · Application 1020140052705
CN · Published · 2013-05 · Application 201810089022.8
US · Registered · 2013-05 · Application 14403121
Registered · 2013-05 · Application 1020130057412
EP · Published · 2013-05 · Application 18215244.7
EP · Registered · 2013-05 · Application 13794539.0
JP · Registered · 2013-05 · Application 27513901
Rejected · 2012-04 · Application 1020120044823
Rejected · 2012-04 · Application 1020120044824
EP · Registered · 2011-09 · Application 19174058.8
EP · Registered · 2011-09 · Application 11834541.2
Registered · 2009-06 · Application 1020090049131
Expired · 2006-09 · Application 1020060086696
Expired · 2006-09 · Application 2020060024276
Expired · 2006-09 · Application 1020060086918
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- OpenAIOAI-SearchBot32
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for OliX Pharmaceuticals, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition